Cargando…

Association of factor expression levels with annual bleeding rate in people with haemophilia B

INTRODUCTION: Gene therapy clinical trials measure steady‐state clotting factor expression levels (FELs) to evaluate the modulation of the bleeding phenotype, aiming to offer consistent protection against breakthrough bleeding events. The link between FELs and bleeding risk in people with haemophili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burke, Tom, Shaikh, Anum, Ali, Talaha M., Li, Nanxin, Konkle, Barbara A., Noone, Declan, O'Mahony, Brian, Pipe, Steven, O'Hara, Jamie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099781/ https://www.ncbi.nlm.nih.gov/pubmed/36331904 http://dx.doi.org/10.1111/hae.14675

Ejemplares similares

Relationship between bleeding episodes, health‐related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study
por: O'Hara, Jamie, et al.
Publicado: (2022)

Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment
por: Witkop, Michelle, et al.
Publicado: (2021)

Achieving the unimaginable: Health equity in haemophilia
por: Skinner, Mark W., et al.
Publicado: (2019)

Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders
por: Kaczmarek, Radoslaw, et al.
Publicado: (2021)

Evidence of a disability paradox in patient‐reported outcomes in haemophilia
por: O’Hara, Jamie, et al.
Publicado: (2021)

Evolution of Haemophilia Care in Europe: 10 years of the principles of care
por: Noone, D., et al.
Publicado: (2020)

Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe
por: Burke, Tom, et al.
Publicado: (2021)

A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen
por: Kennedy, Megan, et al.
Publicado: (2021)

The cost of severe haemophilia in Europe: the CHESS study
por: O’Hara, Jamie, et al.
Publicado: (2017)

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia
por: Skinner, MW., et al.
Publicado: (2018)

How to discuss gene therapy for haemophilia? A patient and physician perspective
por: Miesbach, Wolfgang, et al.
Publicado: (2019)

The endothelial specific isoform of type XVIII collagen correlates to annual bleeding rate in haemophilia patients
por: Kjeld, Nadja Gad, et al.
Publicado: (2018)

Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys
por: Burke, Tom, et al.
Publicado: (2021)

Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study
por: Kennedy, Megan, et al.
Publicado: (2022)

European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018)

Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study
por: Rodriguez-Santana, Idaira, et al.
Publicado: (2022)

Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study
por: Rodriguez-Santana, Idaira, et al.
Publicado: (2022)

The relationship between target joints and direct resource use in severe haemophilia
por: O’Hara, Jamie, et al.
Publicado: (2018)

Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics
por: Farrugia, Albert, et al.
Publicado: (2015)

The impact of severe haemophilia and the presence of target joints on health-related quality-of-life
por: O’Hara, Jamie, et al.
Publicado: (2018)

European principles of inhibitor management in patients with haemophilia: implications of new treatment options
por: Hermans, C., et al.
Publicado: (2020)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Economic burden of hemophilia B in the US: a systematic literature review
por: Li, Nanxin (Nick), et al.
Publicado: (2019)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Physical activity, physical fitness and cardiometabolic risk amongst adults with moderate and severe haemophilia
por: Kennedy, Megan, et al.
Publicado: (2022)

Examining patient and professional perspectives in the UK for gene therapy in haemophilia
por: Woollacott, Ione, et al.
Publicado: (2022)

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
por: Meeks, Shannon L., et al.
Publicado: (2019)

Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria
por: Sibartie, Shomik, et al.
Publicado: (2009)

Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors
por: Golestani, Mina, et al.
Publicado: (2014)

Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
por: Konkle, Barbara, et al.
Publicado: (2020)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
por: Parnes, Aric, et al.
Publicado: (2021)

A new measure to assess pain in people with haemophilia: The Multidimensional Haemophilia Pain Questionnaire (MHPQ)
por: Paredes, Ana Cristina, et al.
Publicado: (2018)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia
por: ALMAGRO, D, et al.
Publicado: (2011)

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
por: Pipe, Steven W., et al.
Publicado: (2022)

Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia
por: Broderick, Carolyn R, et al.
Publicado: (2008)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Inappropriate prescribing and adverse drug events in older people
por: Hamilton, Hilary J, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lp836p07s88u1bdplndkfoqkto